



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

DAVIS et al.

Atty. Ref.: 620-148

Serial No. 09/897,412

Group: 1647

Filed: July 3, 2001

Examiner: Nichols, C.

For: USE OF SECRETIN-RECEPTOR LIGANDS IN
TREATMENT OF CYSTIC FIBROSIS (CF) AND CHRONIC
OBSTRUCTIVE PULMONARY DISEASE (COPD)

* * * * *

Assistant Commissioner for Patents
Washington, DC 20231

October 14, 2003

Sir:

INFORMATION DISCLOSURE STATEMENT

- ☐ 1. **PTO-1449 Pursuant to 37 CFR 1.97(b)**
[within 3 months of filing or prior to 1st Office Action on the merits]
N/C
- ☒ 2.(a) **Statement Pursuant to 37 CFR 1.97(c)**
[before Final Office Action or Allowance (requires Rule 97(e)
Statement or Rule 17(p) fee)]
N/C
- ☐ 2.(b) **Fee Payment Pursuant to 37 CFR 1.97(c)**
[before Final Office Action or Allowance (requires Rule 97(e)
Statement or Rule 17(p) fee)]
\$180.00
- ☐ 3. **Pursuant to 37 CFR 1.97(d)**
[after Final Office Action or Allowance (requires Rule 97(e)
Statement and Rule 17(p) fee), but before final fee payment]
\$180.00

The following are submitted in the above-identified application in compliance with
37 C.F.R. §§ 1.97 and 1.98:

- ☒ 4. A list of documents on Form PTO-1449 together with copies of each
identified document and a translation or a concise explanation of

each non-English language document (such as attached
International Search Report dated 26/09/2003) is enclosed herewith.

This paper is submitted in accordance with:

- ☐ 5. 37 CFR 1.97(b): [within 3 months of filing or prior to 1st Office Action]
- ☒ 6. 37 CFR 1.97(c): [before Final Office Action or Allowance, whichever is earlier];
and
 - ☒ a) The required Statement made in item 8 below; or
 - ☐ b) The \$180.00 fee specified in 37 CFR §1.17(p) for submission of this
Information Disclosure Statement is authorized in item 9 below.
- ☐ 7. 37 CFR §1.97(d): [after Final Office Action or Allowance (requires Rule 97(e)
Statement and Rule 17(p) fee), but before final fee payment]; and
 - ☐ a) The fee (\$180.00) required by 37 CFR §1.17(p) is submitted herewith;
and
 - ☐ b) The required Statement is stated in item 8 below.
- ☒ 8. Statement under 37 CFR 1.97(e)
 - ☒ a) The undersigned attorney of record hereby certifies under 37 C.F.R.
§1.97(e) that each item of information contained in this Information
Disclosure Statement was first cited in a communication from a foreign
patent office in a counterpart foreign application not more than three
months prior to the filing of this Information Disclosure Statement (each
item contained in this IDS was the first citation of that item by a foreign
patent office in a counterpart foreign application which occurred no more
than three months prior to the filing of this IDS); or
 - ☐ b) No item of information contained in this Information Disclosure Statement
was cited in a communication from a foreign patent office in a counterpart
foreign application, and, to the knowledge of the person signing this
Statement, after making reasonable inquiry, no item of information
contained in this Statement was known to any individual designated in 37
CFR §1.56(c) more than three months prior to the filing of this Information
Disclosure Statement.
- ☒ 9. Please charge all deficiency fees associated with the submission of this
Information Disclosure Statement and any other fees applicable to this
application to Deposit Account No. 14-1140. An original and one (1) copy of
this document are enclosed.

DAVIS et al.
Serial No. 09/897,412

Respectfully submitted,
NIXON & VANDERHYE P.C.

By: _____



B. J. Sadoff

Reg. No. 36,663

1100 North Glebe Road, 8th Floor
Arlington, VA 22201-4714
Telephone: (703) 816-4000
Facsimile: (703) 816-4100

